CSCIF · COSCIENS Biopharma Inc.
Market Cap
$4.96M
Shares
996,166
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.98
Open$4.98
Day$4.98–4.98
52W close$0.79–7.00
Avg vol 30d2K
Short int2K · 0.2% float · 2.8d
Short vol0%
DataMay 2024–Aug 2026
Raw chart and full-history price indicators begin at the captured split on May 3, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+95%
above
Price vs 50-day avg
+28%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
67%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−17%
trailing
6-month return
+142%
trailing
YTD return
+142%
this year
Relative strength
+127%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Distributing
-88% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.16% of float · ▲ +57.7% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2 holders — near 1-yr low, contrarian setup
Squeeze score
48
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
230%
annualized · 1-yr
Max drawdown
−82%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+95%
Bullish
Price vs 50-day avg
+28%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
67%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow
Distributing
-88% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.16% of float · ▲ +57.7% MoM · 2.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
2 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $5 · 67%
Range high $7
vs 200-day avg +95%
vs 50-day avg +28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CSCIF
this stock
COSCIENS Biopharma Inc.
|
$4.96M | +141.7% | — | — | 0.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +2.9% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
2
- % held
- 0.4%
- Net QoQ
- -22.9K sh
- Top holder
- TD Waterhouse Canada Inc.
Held
Float
Short & Settlement
Performance
Raw-price comparisons begin at the captured split on May 3, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CSCIF | -3.9% | -17.0% | +141.8% | -3.1% | +141.8% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -5.0% | -21.0% | +127.1% | -6.3% | +128.7% |